keyword
MENU ▼
Read by QxMD icon Read
search

Pharma

keyword
https://www.readbyqxmd.com/read/28724183/physiological-intra-cytoplasmic-sperm-injection-picsi-outcomes-after-oral-pretreatment-and-semen-incubation-with-myo-inositol-in-oligoasthenoteratozoospermic-men-results-from-a-prospective-randomized-controlled-trial
#1
T Korosi, C Barta, K Rokob, T Torok
OBJECTIVE: The aim of the current study was to evaluate the effect of an oral pretreatment with a mix of myo-inositol (Myo-Ins), folic acid, vitamin E, L-carnitine, L-arginine and selenium (Folandrol, Exeltis, Hungary) and subsequent direct Myo-Ins incubation of spermatozoa before Physiological Intra-Cytoplasmic Sperm Injection (PICSI) procedures in infertile couples due to oligoasthenoteratozoospermia with previous failed PICSI procedures. PATIENTS AND METHODS: We performed a prospective, randomized controlled trial at the Assisted Reproduction Unit of the Kaáli Institute (Győr, Hungary)...
June 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28716215/clinical-and-radiographic-assessment-of-the-efficacy-of-a-collagen-membrane-in-regenerative-endodontics-a-randomized-controlled-clinical%C3%A2-trial
#2
Xijun Jiang, He Liu, Chufang Peng
INTRODUCTION: Recent reviews confirm a general lack of randomized, controlled clinical studies on the efficacy of regenerative endodontics in immature teeth affected by pulp and periapical diseases. Moreover, we have no evidence of the curative efficacy of collagen membranes used as scaffolds in regenerative endodontics. Here, we evaluated whether a Bio-Gide collagen membrane (Geistlich Pharma AG, Wolhusen, Switzerland) has efficacy in promoting dentin formation in regenerative endodontics...
July 14, 2017: Journal of Endodontics
https://www.readbyqxmd.com/read/28704211/how-to-emerge-from-the-conservatism-in-clinical-research-methodology
#3
Nuria Kotecki, Nicolas Penel, Ahmad Awada
PURPOSE OF REVIEW: Despite recent changes in clinical research methodology, many challenges remain in drug development methodology. RECENT FINDINGS: Advances in molecular biology and cancer treatments have changed the clinical research landscape. Thus, we moved from empirical clinical oncology to molecular and immunological therapeutic approaches. Along with this move, adapted dose-limiting toxicities definitions, endpoints, and dose escalation methods have been proposed...
July 12, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28700560/ai-powered-drug-discovery-captures-pharma-interest
#4
Eric Smalley
No abstract text is available yet for this article.
July 12, 2017: Nature Biotechnology
https://www.readbyqxmd.com/read/28697715/conversion-from-once-daily-prolonged-release-tacrolimus-to-once-daily-extended-release-tacrolimus-in-stable-liver-transplant-recipients
#5
Mario Altieri, Guillaume Delaval, Elisabeth Kimmoun, Manon Allaire, Ephrem Salamé, Jérôme Dumortier
OBJECTIVES: After organ transplant, strategies to simplify the therapeutic regimen may improve adherence and prevent rejection and/or graft loss. The aim of the present study was to evaluate the safety of conversion from once-daily prolonged-release tacrolimus (Advagraf; Astellas Pharma Europe Limited, Middlesex, UK) to once-daily extended-release tacrolimus (Envarsus; Chiesi SAS, Nanterre, France) in stable adult liver transplant recipients. MATERIALS AND METHODS: This observational study inclu-ded 44 liver transplant patients (median age of 59 y; 63...
July 11, 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28697290/pharmacotherapy-for-obesity
#6
Phong Ching Lee, John Dixon
BACKGROUND: Obesity is a serious, chronic, relapsing disease of energy regulation, with strong genetic and early-life environmental determinants. Pharmacotherapy can be a useful adjunct to lifestyle intervention in effecting and maintaining clinically meaningful weight loss. OBJECTIVE: The aim of this article is to discuss the role of pharmacotherapy in obesity management. The efficacy, side effects and contraindications of available weight-loss medications are reviewed...
2017: Australian Family Physician
https://www.readbyqxmd.com/read/28696792/direct-to-consumer-genetic-testing-and-orphan-drug-development
#7
Matthew Mason, James Levenson, John Quillin
Since the introduction of the Orphan Drug Act (ODA) in 1983, orphan drug approvals in the United States have jumped from <100 per decade to over 200 per year. This growth is widely attributed to the financial incentives the ODA gives to companies that develop these medicines, and it is likely to continue for a unique reason: partnerships between pharmaceutical firms and direct-to-consumer (DTC) genetic testing companies. This emerging trend is the subject of this article, which begins by considering how rare-disease drugs are regulated and the rising interest in nonclinical genetic testing...
July 11, 2017: Genetic Testing and Molecular Biomarkers
https://www.readbyqxmd.com/read/28694321/lisa-anson-pharma-s-new-figurehead-wants-to-let-light-into-the-industry
#8
Anne Gulland
No abstract text is available yet for this article.
July 10, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28694317/family-physicians-support-open-pharma
#9
Wendy Glauser
No abstract text is available yet for this article.
July 10, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/28692267/is-multitask-deep-learning-practical-for-pharma
#10
Bharath Ramsundar, Bowen Liu, Zhenqin Wu, Andreas Verras, Matthew Tudor, Robert P Sheridan, Vijay S Pande
Multitask deep learning has emerged as a powerful tool for computational drug discovery. However, despite a number of preliminary studies, multitask deep networks have yet to be widely deployed in the pharmaceutical and biotech industries. This lack of acceptance stems from both software difficulties and from lack of understanding of the robustness of multitask deep networks. Our work aims to resolve both of these barriers to adoption. We introduce a high-quality open-source implementation of multitask deep networks as part of the DeepChem open-source platform...
July 10, 2017: Journal of Chemical Information and Modeling
https://www.readbyqxmd.com/read/28687936/prevalence-of-lower-urinary-tract-symptoms-in-china-taiwan-and-south-korea-results-from-a-cross-sectional-population-based-study
#11
Christopher Chapple, David Castro-Diaz, Yao-Chi Chuang, Kyu-Sung Lee, Limin Liao, Shih-Ping Liu, Jianye Wang, Tag Keun Yoo, Romeo Chu, Budiwan Sumarsono
INTRODUCTION: Few population-based data are available evaluating the prevalence of lower urinary tract symptoms (LUTS) in Asia. The objective of our study was to determine LUTS prevalence in China, Taiwan, and South Korea using International Continence Society (ICS) 2002 criteria. METHODS: An Internet-based self-administered survey among individuals aged at least 40 years with the ability to use a computer and to read the local language. Survey questions included ICS symptom definitions and the international prostate symptom score (IPSS)...
July 7, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28677079/esi-ms-studies-of-the-reactions-of-novel-platinum-ii-complexes-containing-o-o-chelated-acetylacetonate-and-sulfur-ligands-with-selected-model-proteins
#12
Tiziano Marzo, Sandra A De Pascali, Chiara Gabbiani, Francesco P Fanizzi, Luigi Messori, Alessandro Pratesi
A group of mixed-ligand Pt(II) complexes bearing acetylacetonate and sulphur ligands were recently developed in the University of Lecce as a new class of prospective anticancer agents that manifested promising pharma-cological properties in preliminary in vitro and in vivo tests. Though modelled on the basis of cisplatin, these Pt(II) complexes turned out to exhibit a profoundly distinct mode of action as they were found to act mainly on non-genomic targets rather than on DNA. Accordingly, we have explored here their reactions with two representative model proteins through an established ESI-MS procedure with the aim to describe their general interaction mechanism with protein targets...
July 4, 2017: Biometals: An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine
https://www.readbyqxmd.com/read/28670578/postgraduate-courses-in-pharmaceutical-medicine-in-italy
#13
REVIEW
Domenico Criscuolo
Italy has a significant tradition of excellence in the area of clinical trials (CTRs): important achievements in the clinical development of rifampicin and adriamycin, the two most famous drugs discovered in the research laboratories of two Italian pharmaceutical companies, paved the way to the establishment of a culture of clinical development, mainly in the areas of antimicrobials and oncology. Despite the fact that now the Italian market of pharmaceuticals is largely dominated by multinational companies with headquarters outside Italy, the contribution of Italian studies to the clinical development of new drugs is still significant...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28658307/the-reasons-behind-medicine-shortages-from-the-perspective-of-pharmaceutical-companies-and-pharmaceutical-wholesalers-in-finland
#14
Kati Heiskanen, Riitta Ahonen, Risto Kanerva, Pekka Karttunen, Johanna Timonen
The aim of this study was to explore the reasons behind medicine shortages from the perspective of pharmaceutical companies and pharmaceutical wholesalers in Finland. The study took the form of semi-structured interviews. Forty-one pharmaceutical companies and pharmaceutical wholesalers were invited to participate in the study. The pharmaceutical companies were the member organizations of Pharma Industry Finland (PIF) (N = 30) and the Finnish Generic Pharmaceutical Association (FGPA) (N = 7). One company which is a central player in the pharmaceutical market in Finland but does not belong to PIF or FGPA was also invited...
2017: PloS One
https://www.readbyqxmd.com/read/28656944/a-comparative-pharmacokinetics-study-of-the-anti-parkinsonian-drug-pramipexole
#15
Ratih S I Putri, Effi Setiawati, Syifa A Aziswan, Fenny Ong, Raymond R Tjandrawinata, Liana W Susanto
The present study aimed to compare pharmacokinetic parameters of two pramipexole 0.25 mg formulations in order to show bioequivalence. The study was conducted in a randomized, open-label, two-period, two-sequence, and crossover design, involving 23 healthy volunteers. One of the 0.25 mg formulations of pramipexole evaluated in the study was manufactured by PT Dexa Medica, Palembang, Indonesia, the other, used as the reference, by Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany. All eligible subjects were required to fast before each drug administration period, which was separated by a one-week washout period...
November 18, 2016: Scientia Pharmaceutica
https://www.readbyqxmd.com/read/28645776/selective-inhibition-of-flt3-by-gilteritinib-in-relapsed-or-refractory-acute-myeloid-leukaemia-a-multicentre-first-in-human-open-label-phase-1-2-study
#16
Alexander E Perl, Jessica K Altman, Jorge Cortes, Catherine Smith, Mark Litzow, Maria R Baer, David Claxton, Harry P Erba, Stan Gill, Stuart Goldberg, Joseph G Jurcic, Richard A Larson, Chaofeng Liu, Ellen Ritchie, Gary Schiller, Alexander I Spira, Stephen A Strickland, Raoul Tibes, Celalettin Ustun, Eunice S Wang, Robert Stuart, Christoph Röllig, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, Mark Levis
BACKGROUND: Internal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit of FLT3 inhibitors in patients with acute myeloid leukaemia has been limited by rapid generation of resistance mutations, particularly in codon Asp835 (D835). We aimed to assess the highly selective oral FLT3 inhibitor gilteritinib in patients with relapsed or refractory acute myeloid leukaemia. METHODS: In this phase 1-2 trial, we enrolled patients aged 18 years or older with acute myeloid leukaemia who either were refractory to induction therapy or had relapsed after achieving remission with previous treatment...
June 20, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28643627/bifidobacteria-and-their-health-promoting-effects
#17
Claudio Hidalgo-Cantabrana, Susana Delgado, Lorena Ruiz, Patricia Ruas-Madiedo, Borja Sánchez, Abelardo Margolles
Bifidobacteria are members of the intestinal microbiota of mammals and other animals, and some strains are able to exert health-promoting effects. The genus Bifidobacterium belongs to the Actinobacteria phylum. Firmicutes, Bacteroidetes, and Actinobacteria constitute the most abundant phyla in the human intestinal microbiota, Firmicutes and Bacteroidetes being predominant in adults, and Actinobacteria in breast-fed infants, where bifidobacteria can reach levels higher than 90% of the total bacterial population...
June 2017: Microbiology Spectrum
https://www.readbyqxmd.com/read/28635655/from-farm-to-pharma-an-overview-of-industrial-heparin-manufacturing-methods
#18
REVIEW
Jan-Ytzen van der Meer, Edwin Kellenbach, Leendert J van den Bos
The purification of heparin from offal is an old industrial process for which commercial recipes date back to 1922. Although chemical, chemoenzymatic, and biotechnological alternatives for this production method have been published in the academic literature, animal-tissue is still the sole source for commercial heparin production in industry. Heparin purification methods are closely guarded industrial secrets which are not available to the general (scientific) public. However by reviewing the academic and patent literature, we aim to provide a comprehensive overview of the general methods used in industry for the extraction of heparin from animal tissue...
June 21, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28631242/relationship-between-duration-of-type-2-diabetes-and-effectiveness-of-dpp-4-inhibitor-versus-sulfonylurea-as-add-on-therapy-a-post-hoc-analysis
#19
Helmut Brath, Päivi M Paldánius, Giovanni Bader, Chantal Mathieu
INTRODUCTION: To assess the impact of duration of type 2 diabetes on glucose-lowering effectiveness of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin versus sulfonylureas (SUs) in a real-life setting. METHODS: Data were extracted from the large 1-year, observational EDGE study (N = 45,868). Patients receiving either DPP-4 inhibitor or any SU as add-on to monotherapy were selected (N = 36,164). Impact of the disease duration on change in glycated hemoglobin (HbA1c) levels was evaluated by using a linear multiple regression model...
June 19, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28631217/24-month-open-label-teriparatide-once-weekly-efficacy-research-trial-examining-bone-mineral-density-in-subjects-with-primary-osteoporosis-and-high-fracture-risk
#20
Toshitsugu Sugimoto, Masataka Shiraki, Masao Fukunaga, Hiroshi Hagino, Teruki Sone, Tetsuo Nakano, Hideaki Kishimoto, Masako Ito, Hideki Yoshikawa, Mitsukazu Kishida, Chika Irie, Toshitaka Nakamura
INTRODUCTION: To clarify the additional efficacy and safety benefits of 24 months' treatment with the once-weekly formulation of teriparatide, which is currently used for 72 weeks. METHODS: This was a multicenter, open-label, single-arm study conducted in Japan. Subjects who were 65 years or older with prevalent vertebral fractures received once-weekly subcutaneous injection of 56.5 μg teriparatide for 24 months. The main outcome measure was percentage change from baseline in lumbar (L2-L4) BMD measured by dual-energy X-ray absorptiometry...
June 19, 2017: Advances in Therapy
keyword
keyword
7232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"